i have a patient i want to start on Glow

To start a patient on Glow, it is important to consider the context of BPC-157, which is a synthetic pentadecapeptide with a preclinical evidence base primarily from rodent models. BPC-157 has been associated with promoting angiogenesis, modulating growth factor pathways, and enhancing tissue repair, particularly in tendon, ligament, muscle, and gastrointestinal tissues [1]. However, the human evidence is limited, and claims should be framed as preclinical and hypothesis-generating. Safety data in humans are scarce, and the regulatory status of BPC-157 varies by jurisdiction, as it is not approved as a drug in many regions [1]. If considering BPC-157 for your patient, it is recommended to monitor for potential injection-site reactions and to assess inflammatory markers regularly [5]. Please remember that this information is for decision support only and does not constitute a treatment recommendation or dosing guidance.